Antimicrobial and immunomodulatory activities of porcine cathelicidin Protegrin-1

• Published in: Molecular immunology Vol. 173; pp. 100 - 109
• Main Authors: Javed, Ali, Oedairadjsingh, Trishana, Ludwig, Irene S., Wood, Thomas M., Martin, Nathaniel I., Broere, Femke, Weingarth, Markus H., Veldhuizen, Edwin J.A.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.09.2024
• Subjects: AMP; Animals; Anti-Infective Agents - pharmacology; Antimicrobial Cationic Peptides - immunology; Antimicrobial Cationic Peptides - pharmacology; Cathelicidins; Immunologic Factors - pharmacology; Immunomodulation; Leishmania; Lipopolysaccharides - pharmacology; LPS neutralization; Macrophages - drug effects; Macrophages - immunology; Mice; Phagocytosis; Phagocytosis - drug effects; RAW 264.7 Cells; Swine; AMP; Immunomodulation; LPS neutralization; Leishmania; Phagocytosis
• ISSN: 0161-5890; 1872-9142; 1872-9142
• DOI: 10.1016/j.molimm.2024.07.011

Antimicrobial peptides (AMPs) are a promising alternative to antibiotics in the fight against multi-drug resistant and immune system-evading bacterial infections. Protegrins are porcine cathelicidins which have been identified in porcine leukocytes. Protegrin-1 is the best characterized family member and has broad antibacterial activity by interacting and permeabilizing bacterial membranes. Many host defense peptides (HDPs) like LL-37 or chicken cathelicidin 2 (CATH-2) have also been shown to have protective biological functions during infections. In this regard, it is interesting to study if Protegrin-1 has the immune modulating potential to suppress unnecessary immune activation by neutralizing endotoxins or by influencing the macrophage functionality in addition to its direct antimicrobial properties. This study showed that Protegrin-1 neutralized lipopolysaccharide- (LPS) and bacteria-induced activation of RAW macrophages by binding and preventing LPS from cell surface attachment. Furthermore, the peptide treatment not only inhibited bacterial phagocytosis by murine and porcine macrophages but also interfered with cell surface and intracellular bacterial survival. Lastly, Protegrin-1 pre-treatment was shown to inhibit the amastigote survival in Leishmania infected macrophages. These experiments describe an extended potential of Protegrin-1’s protective role during microbial infections and add to the research towards clinical application of cationic AMPs. •Protegrin-1 neutralizes LPS- and bacteria-induced activation of RAW macrophages.•Protegrin-1 binds LPS and prevents its attachment to macrophage’s cell surface.•Protegrin-1 neutralizes DPLA with more affinity than MPLA.•Bacterial phagocytosis is inhibited by Protegrin-1 treatment of murine and porcine macrophages.•Amastigote burden of Leishmania-infected RAW macrophages is lowered by Protegrin-1 treatment.